Philadelphia biotech firm backed by more than $130M names new CEO
A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.
Northern Ontario mom trying to raise awareness, hope for families dealing with rare diseases
Her mother, Kelsey, living in Espanola, about 40 minutes west of Sudbury, welcomes all the activity because Iris has a rare, ...
Clinical Trials Arena on MSN1d
Maze Therapeutics doses first subject in Phase II AKD treatment trial
Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...
Hosted on MSN19d
First patient dosed in Phase Ib Pompe disease trial
Aro Biotherapeutics has dosed the first patient in a Phase Ib trial of ABX1100, a novel treatment for late-onset Pompe disease (LOPD), a rare inherited disorder that causes progressive muscle ...
pharmaphorum2d
Sanofi extends its Pompe range with first Nexviazyme OK
Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...
BioPharma Dive12d
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...